The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders | Zendy

Robert Aude | Zendy; Pujals Anaïs | Zendy; Favre Loetitia | Zendy; Debernardi Justine | Zendy; Wiels Joëlle | Zendy

Open Access

The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders

Author(s) -

Robert Aude,

Pujals Anaïs,

Favre Loetitia,

Debernardi Justine,

Wiels Joëlle

Publication year - 2020

Publication title -

molecular oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.332

H-Index - 88

eISSN - 1878-0261

pISSN - 1574-7891

DOI - 10.1002/1878-0261.12759

Subject(s) - post transplant lymphoproliferative disorder , lymphoproliferative disorders , medicine , cancer research , immunology , epstein–barr virus , virology , pharmacology , computational biology , biology , virus , lymphoma

Tumor cells infected by Epstein–Barr virus (EBV) express latency proteins, among which LMP1 is able to increase the level of the anti‐apoptotic protein BCL‐2, today considered as an attractive target for therapeutic strategies. Our results suggest that agents targeting BCL‐2, used either alone or in combination with rituximab, represent a novel promising approach for post‐transplant EBV‐positive B lymphoproliferative disorder treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research